Candel therapeutics to host investor conference call featuring expert clinical perspectives on can-2409 phase 3 prostate cancer data following 2025 asco presentation

Needham, mass., may 27, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that candel management will host a webcast and conference call on tuesday, june 3, 2025, at 1:00pm et. the call will discuss the company's positive phase 3 clinical results for can-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. the discussion will follow dr. theodore deweese's* oral presentation at the 2025 american society of clinical oncology (asco) annual meeting.
CADL Ratings Summary
CADL Quant Ranking